{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T23:05:35Z","timestamp":1794870335832,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T00:00:00Z","timestamp":1552867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T00:00:00Z","timestamp":1552867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"U.S. Department of Health &amp; Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01GM118653"],"award-info":[{"award-number":["R01GM118653"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA185690"],"award-info":[{"award-number":["R21CA185690"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Deferiprone (DFP) is a hydroxypyridinone-derived iron chelator currently in clinical use for iron chelation therapy. DFP has also been known to elicit antiproliferative activities, yet the mechanism of this effect has remained elusive. We herein report that DFP chelates the Fe<jats:sup>2+<\/jats:sup>ion at the active sites of selected iron-dependent histone lysine demethylases (KDMs), resulting in pan inhibition of a subfamily of KDMs. Specifically, DFP inhibits the demethylase activities of six KDMs - 2A, 2B, 5C, 6A, 7A and 7B - with low micromolar IC<jats:sub>50<\/jats:sub>s while considerably less active or inactive against eleven KDMs - 1A, 3A, 3B, 4A-E, 5A, 5B and 6B. The KDM that is most sensitive to DFP, KDM6A, has an IC<jats:sub>50<\/jats:sub>that is between 7- and 70-fold lower than the iron binding equivalence concentrations at which DFP inhibits ribonucleotide reductase (RNR) activities and\/or reduces the labile intracellular zinc ion pool. In breast cancer cell lines, DFP potently inhibits the demethylation of H3K4me3 and H3K27me3, two chromatin posttranslational marks that are subject to removal by several KDM subfamilies which are inhibited by DFP in cell-free assay. These data strongly suggest that DFP derives its anti-proliferative activity largely from the inhibition of a sub-set of KDMs. The docked poses adopted by DFP at the KDM active sites enabled identification of new DFP-based KDM inhibitors which are more cytotoxic to cancer cell lines. We also found that a cohort of these agents inhibited HP1-mediated gene silencing and one lead compound potently inhibited breast tumor growth in murine xenograft models. Overall, this study identified a new chemical scaffold capable of inhibiting KDM enzymes, globally changing histone modification profiles, and with specific anti-tumor activities.<\/jats:p>","DOI":"10.1038\/s41598-019-39214-1","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T18:46:13Z","timestamp":1553021173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Deferiprone: Pan-selective Histone Lysine Demethylase Inhibition Activity and Structure Activity Relationship Study"],"prefix":"10.1038","volume":"9","author":[{"given":"Verjine","family":"Khodaverdian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhasish","family":"Tapadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5054-1441","authenticated-orcid":false,"given":"Ian A.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Yi","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragya","family":"Rajpurohit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhakti A.","family":"Sanghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4202-1638","authenticated-orcid":false,"given":"Muthusamy","family":"Thangaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel A.","family":"Hathaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adegboyega K.","family":"Oyelere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,18]]},"reference":[{"key":"39214_CR1","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.2174\/0929867043364685","volume":"11","author":"GJ Kontoghiorghes","year":"2004","unstructured":"Kontoghiorghes, G. J., Pattichis, K., Neocleous, K. & Kolnagou, A. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr. Med. Chem. 11, 2161\u20132183 (2004).","journal-title":"Curr. Med. Chem."},{"key":"39214_CR2","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.1039\/c2dt12159j","volume":"41","author":"T Zhou","year":"2012","unstructured":"Zhou, T., Ma, Y., Kong, X. & Hider, R. C. Design of iron chelators with therapeutic application. Dalton Trans. 41, 6371\u20136389 (2012).","journal-title":"Dalton Trans."},{"key":"39214_CR3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1006\/cbir.1999.0407","volume":"23","author":"T Tanaka","year":"1999","unstructured":"Tanaka, T. et al. Apoptosis during iron chelator induced differentiation in F9 embryonal carcinoma cells. Cell Biol. Int. 23, 541\u2013550 (1999).","journal-title":"Cell Biol. Int."},{"key":"39214_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1046\/j.1365-2184.1999.3210063.x","volume":"32","author":"Y Ido","year":"1999","unstructured":"Ido, Y. et al. Induction of apoptosis by hinokitiol, a potent iron chelator, in teratocarcinoma F9 cells is mediated through the activation of caspase-3. Cell Prolif. 32, 63\u201373 (1999).","journal-title":"Cell Prolif."},{"key":"39214_CR5","first-page":"2925","volume":"49","author":"J Blatt","year":"1989","unstructured":"Blatt, J., Taylor, S. R. & Kontoghiorghes, G. J. Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines. Cancer Res. 49, 2925\u20132927 (1989).","journal-title":"Cancer Res."},{"key":"39214_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1365-2141.1995.tb08927.x","volume":"89","author":"D Hileti","year":"1995","unstructured":"Hileti, D., Panayiotodis, P. & Hoffbrand, A. V. Iron chelators induce apoptosis in proliferating cells. Br. J. Haematol. 89, 181\u2013187 (1995).","journal-title":"Br. J. Haematol."},{"key":"39214_CR7","first-page":"755","volume":"24","author":"E Yasumoto","year":"2004","unstructured":"Yasumoto, E. et al. Cytotoxic activity of deferiprone, maltol and related hydroxyketones against human tumor cell lines. Anticancer Res. 24, 755\u2013762 (2004).","journal-title":"Anticancer Res."},{"key":"39214_CR8","first-page":"4591","volume":"52","author":"KP Hoyes","year":"1992","unstructured":"Hoyes, K. P., Hider, R. C. & Porter, J. B. Cell Cycle Synchronization and Growth Inhibition by 3-Hydroxypyridin-4-one Iron Chelators in Leukemia Cell Lines. Cancer Res. 52, 4591\u20134599 (1992).","journal-title":"Cancer Res."},{"key":"39214_CR9","doi-asserted-by":"publisher","first-page":"20291","DOI":"10.1074\/jbc.271.34.20291","volume":"271","author":"CE Cooper","year":"1996","unstructured":"Cooper, C. E. et al. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide red uctase. J. Biol. Chem. 271, 20291\u201320299 (1996).","journal-title":"J. Biol. Chem."},{"key":"39214_CR10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/0041-008X(69)90062-3","volume":"15","author":"EJ Gralla","year":"1969","unstructured":"Gralla, E. J., Stebbins, R. B., Coleman, G. L. & Delahunt, C. S. Toxicity studies with ethyl maltol. Toxicol. Appl. Pharmacol. 15, 604\u2013613 (1969).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"39214_CR11","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1039\/C0SC00544D","volume":"2","author":"LE Scott","year":"2011","unstructured":"Scott, L. E. et al. N-Aryl-substituted 3-(\u03b2-D-glucopyranosyloxy)-2-methyl-4(1H)-pyridinones as agents for Alzheimer\u2019s therapy. Chem Sci. 2, 642\u2013648 (2011).","journal-title":"Chem Sci."},{"key":"39214_CR12","doi-asserted-by":"publisher","first-page":"8388","DOI":"10.1021\/ja0485513","volume":"126","author":"DT Puerta","year":"2004","unstructured":"Puerta, D. T., Lewis, J. A. & Cohen, S. M. New Beginnings for Matrix Metalloproteinase Inhibitors: Identification of High-Affinity Zinc-Binding Groups. J. Am. Chem. Soc. 126, 8388\u20138389 (2004).","journal-title":"J. Am. Chem. Soc."},{"key":"39214_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/cmdc.200600204","volume":"2","author":"FE Jacobsen","year":"2007","unstructured":"Jacobsen, F. E., Lewis, J. A. & Cohen, S. M. The Design of Inhibitors for Medicinally Relevant Metalloproteins. Chem Med Chem 2, 152\u2013171 (2007).","journal-title":"Chem Med Chem"},{"key":"39214_CR14","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1182\/blood.V98.13.3831","volume":"98","author":"KH Maclean","year":"2001","unstructured":"Maclean, K. H., Cleveland, J. L. & Porter, J. B. Cellular zinc content is a major determinant of iron chelator\u2013induced apoptosis of thymocytes. Blood 98, 3831\u20133839 (2001).","journal-title":"Blood"},{"key":"39214_CR15","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1021\/jm301769u","volume":"56","author":"V Patil","year":"2013","unstructured":"Patil, V., Sodji, Q., Kornacki, J., Mrksich, M. & Oyelere, A. K. 3-Hydroxypyridin-2-thiones as a novel zinc binding group for selective HDAC inhibition. J. Med. Chem. 56, 3492\u20133506 (2013).","journal-title":"J. Med. Chem."},{"key":"39214_CR16","doi-asserted-by":"publisher","first-page":"9969","DOI":"10.1021\/jm401225q","volume":"56","author":"Q Sodji","year":"2013","unstructured":"Sodji, Q., Patil, V., Kornacki, J., Mrksich, M. & Oyelere, A. K. Synthesis and Structure\u2212Activity Relationship of 3-Hydroxypyridine-2-thione-Based Histone Deacetylase Inhibitors. J. Med. Chem. 56, 9969\u20139981 (2013).","journal-title":"J. Med. Chem."},{"key":"39214_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4155\/fmc.12.3","volume":"4","author":"B Gryder","year":"2012","unstructured":"Gryder, B., Sodji, Q. & Oyelere, A. K. Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need to Succeed. Future Med. Chem. 4, 505\u2013524 (2012).","journal-title":"Future Med. Chem."},{"key":"39214_CR18","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1101\/gad.172296.111","volume":"25","author":"T Sengoku","year":"2011","unstructured":"Sengoku, T. & Yokoyama, S. Structural basis for histone H3 Lys 27 demethylation by UTX\/KDM6A. Genes Dev. 25, 2266\u20132277 (2011).","journal-title":"Genes Dev."},{"key":"39214_CR19","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1101\/gad.246561.114","volume":"28","author":"Z Cheng","year":"2014","unstructured":"Cheng, Z. et al. A molecular threading mechanism underlies Jumonji lysine demethylase KDM2A regulation of methylated H3K36. Genes Dev. 28, 1758\u20131771 (2014).","journal-title":"Genes Dev."},{"key":"39214_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nsmb.1753","volume":"17","author":"JR Horton","year":"2010","unstructured":"Horton, J. R. et al. Enzymatic and structural insights for substrate specificity of a family of jumonji histone lysine demethylases. Nat Struct. Mol. Biol. 17, 38\u201343 (2010).","journal-title":"Nat Struct. Mol. Biol."},{"key":"39214_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nchembio.2085","volume":"12","author":"M Vinogradova","year":"2016","unstructured":"Vinogradova, M. et al. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. Nat. Chem. Biol. 12, 531\u2013538 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"39214_CR22","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.chembiol.2016.06.006","volume":"23","author":"JR Horton","year":"2016","unstructured":"Horton, J. R. et al. Structural basis for KDM5A histone lysine demethylase inhibition by diverse compounds. Cell Chem. Biol. 23, 769\u2013781 (2016).","journal-title":"Cell Chem. Biol."},{"key":"39214_CR23","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1158\/0008-5472.CAN-13-1896","volume":"74","author":"JH Kim","year":"2014","unstructured":"Kim, J. H. et al. UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. Cancer Res. 74, 1705\u20131717 (2014).","journal-title":"Cancer Res."},{"key":"39214_CR24","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1038\/onc.2015.443","volume":"35","author":"U-H Park","year":"2016","unstructured":"Park, U.-H. et al. ASXL2 promotes proliferation of breast cancer cells by linking ER\u03b1 to histone methylation. Oncogene. 35, 3742\u20133752 (2016).","journal-title":"Oncogene."},{"key":"39214_CR25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455\u2013461 (2010).","journal-title":"J. Comput. Chem."},{"key":"39214_CR26","doi-asserted-by":"publisher","first-page":"30984","DOI":"10.1074\/jbc.M112.341040","volume":"287","author":"A Janzer","year":"2012","unstructured":"Janzer, A. et al. The H3K4me3 Histone Demethylase Fbxl10 is a Regulator of Chemokine Expression, Cellular Morphology, and the Metabolome of Fibroblasts. J. Biol. Chem. 287, 30984\u201330992 (2012).","journal-title":"J. Biol. Chem."},{"key":"39214_CR27","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.cell.2007.02.003","volume":"128","author":"J Christensen","year":"2007","unstructured":"Christensen, J. et al. RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell. 128, 1063\u20131076 (2007).","journal-title":"Cell."},{"key":"39214_CR28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","volume":"128","author":"T Kouzarides","year":"2007","unstructured":"Kouzarides, T. Chromatin modifications and their function. Cell. 128, 693\u2013705 (2007).","journal-title":"Cell."},{"key":"39214_CR29","doi-asserted-by":"publisher","first-page":"9408","DOI":"10.1074\/jbc.M112.419861","volume":"288","author":"J Sayegh","year":"2013","unstructured":"Sayegh, J. et al. Identification of Small Molecule Inhibitors of Jumonji AT-rich Interactive Domain 1B (JARID1B) Histone Demethylase by a Sensitive High Throughput Screen. J. Biol. Chem. 288, 9408\u20139417 (2013).","journal-title":"J. Biol. Chem."},{"key":"39214_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.71","volume":"6","author":"J-Y Chen","year":"2017","unstructured":"Chen, J.-Y. et al. Lysine demethylase KDM2A inhibits TET2 to promote DNA methylation and silencing of tumor suppressor genes in breast cancer. Oncogenesis 6, e369, https:\/\/doi.org\/10.1038\/oncsis.2017.71 (2017).","journal-title":"Oncogenesis"},{"key":"39214_CR31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.yexcr.2017.08.024","volume":"359","author":"N Yan","year":"2017","unstructured":"Yan, N. et al. GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells. Exp Cell Res 359, 405\u2013414 (2017).","journal-title":"Exp Cell Res"},{"key":"39214_CR32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ccr.2011.08.008","volume":"256","author":"MA Santos","year":"2012","unstructured":"Santos, M. A., Marques, S. M. & Chaves, S. Hydroxypyridinones as \u201cprivileged\u201d chelating structures for the design of medicinal drugs. Coordination Chemistry Reviews. 256, 240\u2013259 (2012).","journal-title":"Coordination Chemistry Reviews."},{"key":"39214_CR33","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.cell.2012.03.052","volume":"149","author":"NA Hathaway","year":"2012","unstructured":"Hathaway, N. A. et al. Dynamics and memory of heterochromatin in living cells. Cell. 149, 1447\u20131460 (2012).","journal-title":"Cell."},{"key":"39214_CR34","doi-asserted-by":"publisher","first-page":"767","DOI":"10.4161\/epi.5.8.13278","volume":"5","author":"OI Binda","year":"2010","unstructured":"Binda, O. I. et al. Trimethylation of histone H3 lysine 4 impairs methylation of histone H3 lysine 9: regulation of lysine methyltransferases by physical interaction with their substrates. Epigenetics. 5, 767\u2013775 (2010).","journal-title":"Epigenetics."},{"key":"39214_CR35","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.tiv.2007.07.013","volume":"22","author":"S Adler","year":"2008","unstructured":"Adler, S., Pellizzer, C., Hareng, L., Hartung, T. & Bremer, S. First steps in establishing a developmental toxicity test method based on human embryonic stem cells. Toxicol In Vitro. 22, 200\u2013211 (2008).","journal-title":"Toxicol In Vitro."},{"key":"39214_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1517\/17425255.2012.639763","volume":"8","author":"F Pistollato","year":"2012","unstructured":"Pistollato, F., Bremer-Hoffmann, S., Healy, L., Young, L. & Stacey, G. Standardization of pluripotent stem cell cultures for toxicity testing. Expert Opin Drug Metab Toxicol. 8, 239\u2013257 (2012).","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"39214_CR37","doi-asserted-by":"publisher","first-page":"6654","DOI":"10.1158\/0008-5472.CAN-11-1446","volume":"71","author":"S Elangovan","year":"2011","unstructured":"Elangovan, S. et al. SIRT1 is essential for oncogenic signaling by estrogen\/estrogen receptor \u03b1 in breast cancer. Cancer Res. 71, 6654\u20136664 (2011).","journal-title":"Cancer Res."},{"key":"39214_CR38","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1158\/0008-5472.CAN-13-1451","volume":"74","author":"S Elangovan","year":"2014","unstructured":"Elangovan, S. et al. The niacin\/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival. Cancer Res. 74, 1166\u20131178 (2014).","journal-title":"Cancer Res."},{"key":"39214_CR39","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1177\/1947601911417976","volume":"2","author":"D Rotili","year":"2011","unstructured":"Rotili, D. & Mai, A. Targeting Histone Demethylases: A New Avenue for the Fight against Cancer. Genes Cancer. 2, 663\u2013679 (2011).","journal-title":"Genes Cancer."},{"key":"39214_CR40","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1126\/science.1147674","volume":"319","author":"B Perillo","year":"2008","unstructured":"Perillo, B. et al. DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science 319, 202\u2013206 (2008).","journal-title":"Science"},{"key":"39214_CR41","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.celrep.2014.02.004","volume":"6","author":"J Cao","year":"2014","unstructured":"Cao, J. et al. Histone Demethylase RBP2 Is Critical for Breast Cancer Progression and Metastasis. Cell Reports 6, 868\u2013877 (2014).","journal-title":"Cell Reports"},{"key":"39214_CR42","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.ccr.2014.04.024","volume":"25","author":"S Yamamoto","year":"2014","unstructured":"Yamamoto, S. et al. JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell. 25, 762\u2013777 (2014).","journal-title":"Cancer Cell."},{"key":"39214_CR43","doi-asserted-by":"publisher","first-page":"15633","DOI":"10.1074\/jbc.274.22.15633","volume":"274","author":"PJ Lu","year":"1999","unstructured":"Lu, P. J. et al. A novel gene (PLU-1) containing highly conserved putative DNA\/ chromatin binding motifs is specifically up-regulated in breast cancer. J. Biol. Chem. 274, 15633\u201315645 (1999).","journal-title":"J. Biol. Chem."},{"key":"39214_CR44","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1021\/ml4001084","volume":"4","author":"AW Andayi","year":"2013","unstructured":"Andayi, A. W., Egan, T. J., Gut, J., Rosenthal, P. J. & Chibale, K. Synthesis, Antiplasmodial Activity, and \u03b2-Hematin Inhibition of Hydroxypyridone\u2013Chloroquine Hybrids. ACS Med. Chem. Lett. 4, 642\u2013646 (2013).","journal-title":"ACS Med. Chem. Lett."},{"key":"39214_CR45","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1016\/S0040-4039(01)00282-9","volume":"42","author":"JW Lee","year":"2001","unstructured":"Lee, J. W., Jun, S. I. & Kim, K. An efficient and practical method for the synthesis of mono-N-protected \u03b1,\u03c9-diaminoalkanes. Tet. Lett. 42, 2709\u20132711 (2001).","journal-title":"Tet. Lett."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39214-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39214-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39214-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T22:44:58Z","timestamp":1721083498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39214-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,18]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["39214"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-39214-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,18]]},"assertion":[{"value":"9 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4802"}}